Lineage Cell Therapeutics (XTAE:LCTX) Current Accrued Expense : ₪3.68 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Lineage Cell Therapeutics Current Accrued Expense?

Lineage Cell Therapeutics's Current Accrued Expense for the quarter that ended in Mar. 2024 was ₪3.68 Mil.

Lineage Cell Therapeutics's quarterly Current Accrued Expense increased from Sep. 2023 (₪1.30 Mil) to Dec. 2023 (₪4.08 Mil) but then declined from Dec. 2023 (₪4.08 Mil) to Mar. 2024 (₪3.68 Mil).

Lineage Cell Therapeutics's annual Current Accrued Expense declined from Dec. 2021 (₪82.10 Mil) to Dec. 2022 (₪14.25 Mil) and declined from Dec. 2022 (₪14.25 Mil) to Dec. 2023 (₪4.08 Mil).

Lineage Cell Therapeutics Current Accrued Expense Historical Data

The historical data trend for Lineage Cell Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lineage Cell Therapeutics Current Accrued Expense Chart

Lineage Cell Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

4.63

6.36

82.10

14.25

4.08

Lineage Cell Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															1.50	2.16	1.30	4.08	3.68

Lineage Cell Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Lineage Cell Therapeutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Lineage Cell Therapeutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Lineage Cell Therapeutics (XTAE:LCTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (XTAE:LCTX) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

LCTX:USA BT3:Germany

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008

Website

https://www.lineagecell.com

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cell transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.